in combination with nivolumab in pts with melanoma who progressed during prior anti-PD-1/PD-L1 therapy (mel prior IO) in all-comer and biomarker-enriched populations. Annals of Oncology. 2017;28:v611
Mechanisms of PD-1/PD-L1 blockade PD-1/PD-L1 activity in the CRC microenvironment Monoclonal antibodies in CRC treatment Combination of PD-1 inhibitors and mAbs for cancer therapy Administration of inflammatory agents for CRC therapy Clinical trials and challenges Conclusions Funding Availability of da...
Can Hyperthermia Treatment Restore Sensitivity to Anti-PDL1 Therapy in Immunological Cold Tumors? Lessons Learned from Preclinical Murine Modelsdoi:10.1016/j.ijrobp.2024.07.797Purpose/Objective(s) Immunological "cold" tumors remain a therapeutical challenge for the barren tumor microenvironment (TME) ...
AK131可有效完全抑制CD73的酶学活性,阻断PD-1介导的免疫细胞抑制。 临床前研究中,AK131显示了强大的体内和体外活性,除能有效阻断PD-1/PDL-1相互作用,还可有效地促进T细胞和B细胞的活化,诱导CD73的内吞作用。在小鼠模型中,AK131显示了优越的体内抗肿瘤活性,可几乎100%抑制肿瘤生长。 在近期举办的2022年美国癌症...
Methods: RNA silencing and pharmacologic inhibitors were used to evaluate the functions of CDK7/p38α/MYC/PD- L1 axis in cancer cell proliferation and antiPD-1 therapy resistance. Flow cytometry was performed to detect the status of the immune microenvironment after CDK7 inhibition and antiPD-1...
Anti-PD-1 therapy, effective in patients with various advanced tumors, still encounters the challenge of insensitivity in most patients. Here, we demonstrate that PD-L1 on tumor cell-derived extracellular vesicles (TEVs) is critical for anti-PD-1 therapy resistance. Reducing endogenous and transfer...
Programmed cell death 1 ligand 1 (PDL1)/programmed cell death 1 (PD1) blockade immunotherapy provides a prospective strategy for the treatment of colorectal cancer (CRC), but various constraints on the effectiveness of the treatment are still remaining.
This small retrospective cohort of heavily pretreated unselected patients suggests ipilimumab might reboost the immune response in patients with advanced NSCLC following progression of disease on anti‐PD1 therapy, while delaying exposure to the higher toxicity rates associated with upfront combination ...
7. McDermott D. & Atkins M. 2013. PD-1 as a potential target in cancer therapy. Cancer Med. 2(5): 662–673. Figures Binding specificity to recombinant mouse or human PD-L1 Validation of Anti-PD-L1 InvivoFit™ mAbs by flow cytometry ...
1/PDL1 agents; together, the development of resistance to anti-PD-1/PD-L1 therapy that leads to failure of anti-PD-1/PD-L1 therapy has significantly limited a broad applicability of the findings in clinical practices. Nowadays, several companion diagnostic assays for PDL1 expression have been...